Laurel Wealth Advisors LLC Acquires 29,090 Shares of Thermo Fisher Scientific Inc. $TMO

Laurel Wealth Advisors LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 27,971.2% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 29,194 shares of the medical research company’s stock after buying an additional 29,090 shares during the quarter. Laurel Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $11,837,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of TMO. Mondrian Investment Partners LTD increased its holdings in Thermo Fisher Scientific by 146.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock valued at $106,738,000 after purchasing an additional 127,357 shares in the last quarter. TIAA Trust National Association increased its stake in shares of Thermo Fisher Scientific by 10.5% in the second quarter. TIAA Trust National Association now owns 123,948 shares of the medical research company’s stock valued at $50,256,000 after buying an additional 11,817 shares in the last quarter. Caledonia Investments PLC grew its holdings in Thermo Fisher Scientific by 11.5% during the 2nd quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock worth $45,299,000 after acquiring an additional 11,500 shares during the last quarter. Heritage Investors Management Corp increased its position in Thermo Fisher Scientific by 9.6% in the 2nd quarter. Heritage Investors Management Corp now owns 56,587 shares of the medical research company’s stock valued at $22,944,000 after acquiring an additional 4,971 shares in the last quarter. Finally, Vontobel Holding Ltd. lifted its position in shares of Thermo Fisher Scientific by 4.5% during the second quarter. Vontobel Holding Ltd. now owns 1,089,103 shares of the medical research company’s stock worth $441,588,000 after purchasing an additional 46,743 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 17,104 shares of the stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the completion of the transaction, the chief executive officer owned 113,762 shares in the company, valued at approximately $65,247,057.48. This represents a 13.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael D. Shafer sold 10,725 shares of the business’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total value of $6,435,000.00. Following the completion of the sale, the executive vice president owned 18,731 shares in the company, valued at approximately $11,238,600. This trade represents a 36.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 52,570 shares of company stock valued at $30,382,352. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Trading Down 0.7%

Shares of NYSE TMO opened at $593.41 on Thursday. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The stock has a market cap of $222.95 billion, a price-to-earnings ratio of 34.28, a P/E/G ratio of 3.27 and a beta of 0.82. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The company’s fifty day moving average is $544.05 and its 200-day moving average is $477.35.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter last year, the business posted $5.28 EPS. The firm’s revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its board has approved a stock buyback plan on Thursday, November 6th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 2.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Leerink Partners upped their price objective on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday, October 22nd. Redburn Partners set a $580.00 price target on Thermo Fisher Scientific in a report on Wednesday, October 8th. Barclays boosted their price objective on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Nineteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $601.65.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.